Charles Debrosse
Pediatrics · Cincinnati, OHNPI 1700043155
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,360 of the $134,537 with a category attached, or 88.0%. AstraZeneca accounts for 89.0% of it on its own, with 20 other manufacturers making up the rest. Among pediatrics clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $505.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$120K
- Amgen$11K
- Genentech USA, Inc.$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$293
- GSK$277
- plus $952 from 15 others
What the payments were for
- Consulting fees$6,2585%
- Speaking & faculty fees$118,36088%
- Travel & lodging$7301%
- Food & beverage$9,1557%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 138 | $119,795 |
| Amgen | 27 | $10,551 |
| Genentech USA, Inc. | 4 | $1,523 |
| Sanofi | 33 | $1,146 |
| Regeneron Healthcare Solutions, Inc. | 12 | $293 |
| GSK | 15 | $277 |
| Aimmune Therapeutics, Inc. | 1 | $175 |
| ADMA Biomanufacturing LLC | 8 | $165 |
| Novartis | 7 | $133 |
| CSL Behring | 4 | $132 |
| Pfizer | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Optinose US, Inc. | 1 | $35 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Blueprint Medicines Corporation | 1 | $30 |
| Grifols USA, LLC | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Sanofi US Services Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $17 |
| Jubilant Hollisterstier LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,537 in reported general payments places this provider in the 95th percentile of 2,041 pediatrics providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 56 | $149,745 |
| TezspireTezepelumab-Ekko | 19 | $89,439 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $86,639 |
| Dupixent PenDupilumab | 14 | $58,452 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 16 | $49,318 |
| XembifyImmune Globulin,gamma(Igg)klhw | 12 | $35,960 |
| XhanceFluticasone Propionate | 23 | $22,726 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $21,767 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $17,090 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $16,320 |
| Spiriva RespimatTiotropium Bromide | 20 | $14,419 |
| Arnuity ElliptaFluticasone Furoate | 56 | $11,909 |
| Epinephrine | 57 | $9,600 |
| AirsupraAlbuterol Sulfate/Budesonide | 17 | $7,945 |
| Wixela InhubFluticasone Propion/Salmeterol | 43 | $5,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Airsupra | $119,795 | $119,15265 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $277 | $115,638197 claims |
| Grifols USA, LLCXembify | $25 | $35,96012 claims |
| Optinose US, Inc.Xhance | $35 | $22,72623 claims |
| Hikma Pharmaceuticals USAEpinephrine | $32 | $9,60057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,041 pediatrics providers in Ohio.
Other pediatrics in Cincinnati
- Scott WexelblattCincinnati$64K
- Katherine ZappiaCincinnati$7K
- Paul BunchCincinnati$4K
- Jon DvorakPerrysburg$212K
- Breanne RocheSolon$58K
- Richard BreenHilliard$43K
- Catherine McDanielDayton$34K
- Lisa RichardsToledo$31K
- Kristie RossCleveland$20K
- Jessica CastonguayAkron$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.